JCR Pharmaceuticals

Historical price data

JCR Pharmaceuticals is a publicly traded, revenue-generating biopharma with a strategic focus on lysosomal storage disorders and other rare diseases. Its key achievement is the development and global commercialization of IZCARGO® (pabinafusp alfa), the first intravenously administered enzyme replacement therapy to demonstrate efficacy in treating both the somatic and central nervous system symptoms of Hunter syndrome (MPS II). The company's future direction is heavily invested in leveraging its J-Brain Cargo® platform to develop new treatments for neurodegenerative and other CNS disorders with high unmet medical need.

J-Brain Cargo®: A proprietary blood-brain barrier (BBB) crossing technology utilizing receptor-mediated transcytosis to deliver enzyme replacement therapies and other biologics into the central nervous system.

11 drugs in pipeline, 4 in Phase 3

JCR competes with large pharma (Takeda's Elaprase®) in Hunter syndrome and with biotech platforms (Denali Therapeutics) in CNS-penetrant therapies. Its primary differentiation is the clinically validated J-Brain Cargo® platform, which provides a first-mover advantage in treating the CNS symptoms of LSDs with intravenous administration.